New drug aims to tame antibodies in rare clotting disorder

NCT ID NCT06315530

Completed Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether the drug telitacicept can reduce levels of harmful antibodies in 20 people with antiphospholipid syndrome, a condition that raises the risk of blood clots. Participants received either telitacicept plus standard care or standard care alone for 48 weeks. The main goal was to see if antibody levels dropped, not yet to prove it prevents clots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: telitacicept
What this could lead to: If it works, this could point toward a new way to reduce dangerous antibodies and prevent blood clots in people with antiphospholipid syndrome.
What could go wrong: This is a very small, early-phase trial with only 20 people. It only measures antibody levels, not whether it actually prevents clots. Side effects are not yet well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome primary antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIPHOSPHOLIPID SYNDROME (APS)

Contacts and locations

Locations

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.